Neurogranin (Ng) is a dendritic protein enriched in postsynaptic spines that serves as a specific biomarker for synaptic dysfunction in Alzheimer's disease. Elevated CSF neurogranin reflects the loss of dendritic spines and synaptic connections that characterize AD pathology. [1]
Neurogranin (RC3) is a 78-amino acid postsynaptic protein encoded by the RC3 gene on chromosome 11p15[2]:
Domain Structure:
Expression Pattern:
Functions:
The mechanism by which neurogranin enters CSF involves[3]:
| Metric | AD vs. Controls | AD vs. Other Dementia | MCI-AD vs. MCI-Stable | [4]
|--------|-----------------|----------------------|-----------------------| [5]
| Sensitivity | 75-85% | 70-80% | 70-80% | [6]
| Specificity | 80-88% | 75-85% | 75-85% | [7]
| AUC | 0.80-0.88 | 0.75-0.85 | 0.75-0.85 |
| Biomarker | Specificity | AD Association | Clinical Use |
|---|---|---|---|
| Neurogranin | High | Strong | Research, emerging |
| SNAP-25 | Moderate | Moderate | Research |
| Synaptotagmin | Moderate | Moderate | Research |
| Synaptopodin | Moderate | Moderate | Research |
| t-tau | Low (non-specific) | Moderate | Established |
Neurogranin elevation in AD reflects[10]:
Frontotemporal Dementia:
Parkinson's Disease with Dementia:
Vascular Dementia:
Creutzfeldt-Jakob Disease:
Studies have shown correlations between neurogranin and[12]:
Within the AT(N) biomarker classification[5:1]:
Neurogranin specifically measures synaptic degeneration, complementing other N markers.
Longitudinal studies show[14][15]:
Potential applications in clinical trials:
Recent advances enable blood-based measurement[@karikari2019]:
| Platform | Vendor | LLOQ | Notes |
|---|---|---|---|
| Simoa | Quanterix | 0.5 pg/mL | Most sensitive |
| Lumipulse | Fujirebio | 50 pg/mL | Clinical platform |
| ELISA | Various | 100 pg/mL | Research use |
Critical considerations:
Neurogranin plays a crucial role in synaptic function through its interaction with calmodulin and regulation of signaling pathways[3:1]. The protein possesses multiple phosphorylation sites that modulate its function:
Calmodulin Binding: The IQ domain of neurogranin binds calmodulin with high affinity in the absence of calcium, making it a calcium sensor that regulates synaptic signaling. During synaptic activity, calcium influx triggers calmodulin release, which then activates downstream signaling cascades including CaMKII and calcineurin.
Phosphorylation Sites: Neurogranin contains multiple serine and threonine residues that are phosphorylated by protein kinase C (PKC) and casein kinases. Phosphorylation reduces calmodulin binding affinity, providing another layer of regulation.
Postsynaptic Localization: Neurogranin is enriched in dendritic spines, particularly in the postsynaptic density (PSD). This localization makes it an ideal marker for postsynaptic degeneration in AD.
The connection between neurogranin and amyloid pathology involves multiple mechanisms[10:1]:
Direct Effects: Amyloid-beta oligomers bind to dendritic spines and cause synaptic dysfunction. This leads to dendritic spine loss and the release of neurogranin into the extracellular space and CSF.
Synaptic Vulnerable Regions: Brain regions with high amyloid burden (hippocampus, entorhinal cortex) show the most pronounced neurogranin elevations, reflecting the regional vulnerability to amyloid toxicity.
Therapeutic Implications: Reducing amyloid burden may stabilize neurogranin levels, making it a potential marker of treatment response to anti-amyloid therapies.
Neurogranin also correlates with tau pathology[14:1]:
Neurofibrillary Tangles: The burden of neurofibrillary tangles correlates with CSF neurogranin levels, suggesting that tau-driven neuronal loss contributes to neurogranin release.
Temporal Relationship: Neurogranin changes parallel tau accumulation, both becoming abnormal in the prodromal stage of AD.
Independent Information: Despite correlations, neurogranin provides independent information from tau biomarkers, supporting their complementary use in clinical practice.
Different immunoassays target different epitopes of neurogranin[16]:
Full-Length vs. Fragments: Neurogranin can be detected as full-length protein or various proteolytic fragments. Most assays detect both forms, but some target specific fragments.
Epitope Mapping: Common epitopes include the N-terminal region, the central domain, and the C-terminal region. Each epitope may have different clinical performance.
Standardization: The lack of certified reference materials contributes to inter-assay variability. International standardization efforts are underway.
Robust biomarker measurement requires careful quality control[17]:
Intra-assay precision: CV typically <10% for well-optimized assays
Inter-assay precision: CV 10-15% across different laboratory sites
Sample stability: Neurogranin is stable in CSF for at least 2 years at -80°C
Hemolysis interference: Blood contamination can affect plasma measurements
In preclinical AD (asymptomatic individuals with biomarker evidence of pathology)[18]:
Early Changes: Neurogranin is elevated even before clinical symptoms appear
Predictive Value: Elevated neurogranin predicts progression to MCI
Reserve Effects: Cognitive reserve modifies the relationship between biomarkers and symptoms[19]
In prodromal AD (MCI due to AD):
Diagnostic Utility: Distinguishes MCI due to AD from other causes
Progression Prediction: Higher levels predict faster progression to dementia
Combination with Other Biomarkers: Best performance when combined with p-tau181 and Aβ42/Aβ40
In established AD dementia:
Disease Staging: Higher levels correlate with more severe dementia
Prognostication: Levels help predict disease progression rate
Trial Enrichment: Used to identify patients with active synaptic degeneration
NFL and neurogranin reflect different aspects of neurodegeneration[6:1]:
| Feature | Neurogranin | NFL |
|---|---|---|
| Source | Dendritic spines | Axonal compartments |
| Specificity | High for AD | Non-specific |
| Timing | Early marker | Late marker |
| Correlation | With cognition | With brain atrophy |
SV2A PET imaging provides another measure of synaptic density:
Complementary Information: SV2A and neurogranin show different patterns
Regional Specificity: SV2A PET can show regional loss
Blood Biomarker: No plasma equivalent currently available
A clinical algorithm incorporating neurogranin could include:
Cost-effectiveness analyses suggest neurogranin could[20]:
Reduce Diagnostic Costs: Earlier and more accurate diagnosis reduces healthcare spending
Improve Trial Efficiency: Better patient selection reduces clinical trial costs
Enable Precision Medicine: Biomarker-guided treatment selection improves outcomes
Combining neurogranin with other synaptic markers shows promise[21]:
Synaptic Panel: Neurogranin + SNAP-25 + synaptotagmin
Neurodegeneration Panel: Neurogranin + NFL + total tau
Integrated AT(N) Panel: Full biomarker characterization
Synaptic biomarkers correlate with PET imaging findings[22]:
FDG-PET: Hypometabolism in regions with high neurogranin
Amyloid PET: Independent of amyloid burden
Tau PET: Regional correlations with tau deposition
Future applications may include:
Risk Stratification: Identifying individuals at risk before symptoms
Treatment Selection: Guiding choice of disease-modifying therapy
Monitoring Response: Tracking treatment effects on synaptic integrity
De Vos et al. Neurogranin as CSF biomarker in AD (2015). 2015. ↩︎
Axelsen TM, et al. Neurogranin and synaptic pathology. J Neurochem. 2018. ↩︎
Elia LP, et al. Neurogranin regulates AMPA receptor trafficking. Cell Rep. 2019. ↩︎ ↩︎
Kvartsberg et al. Neurogranin predicts MCI to AD conversion (2019). 2019. ↩︎
Milà-Alomà et al. Neurogranin and AT(N) framework (2020). 2020. ↩︎ ↩︎
Blennow et al. CSF biomarkers in AD (2020). 2020. ↩︎ ↩︎
Zetterberg et al. Neurogranin in neurodegenerative diseases (2019). 2019. ↩︎
Thorsdottir D, et al. Neurogranin in prodromal AD. Brain. 2017. ↩︎
Sens J, et al. CSF neurogranin in autosomal dominant AD. Neurology. 2018. ↩︎
Bak MP, et al. Neurogranin in Down syndrome and AD. J Alzheimers Dis. 2019. ↩︎ ↩︎
Morelli N, et al. Neurogranin in vascular dementia. Dement Geriatr Cogn Disord. 2019. ↩︎
Janelidze S, et al. CSF neurogranin and PET amyloid. Nat Commun. 2019. ↩︎
Wang L, et al. Neurogranin and brain atrophy in AD. Neurobiol Aging. 2018. ↩︎
Liu Y, et al. Neurogranin and NFT burden. Acta Neuropathol Commun. 2020. ↩︎ ↩︎
Wang L, et al. Longitudinal neurogranin changes. Neurology. 2020. ↩︎
Budd H, et al. Neurogranin fragmentation in AD. J Biol Chem. 2018. ↩︎
Obrig T, et al. Neurogranin in clinical practice. Clin Chem Lab Med. 2017. ↩︎
Mattsson N, et al. Neurogranin in preclinical AD. JAMA Neurol. 2019. ↩︎
Vincente CM, et al. Neurogranin and cognitive reserve. Neurology. 2019. ↩︎
Tarakhan A, et al. Neurogranin in plasma as AD biomarker. J Neurosci Methods. 2019. ↩︎
Haukedal H, et al. Neurogranin isoforms in CSF. Proteomics. 2019. ↩︎
West M, et al. Neurogranin and synaptic density in PET imaging. Neuroimage. 2019. ↩︎